New Delhi: Transasia Bio-Medicals, one of India’s leading In-vitro diagnostic company recently organized a scientific seminar in East Delhi on the latest advancements in biochemistry and hematology for laboratories.
Titled Transasia Scientific Seminar (TSS) Ace, this pioneering academic initiative aims at encouraging the exchange of technical know-how among doctors. The seminar focused on biochemistry and hematology – two of the most critical areas for in-vitro diagnostics.
The session on ‘Effective Use of Database Systems by doctors’ by Dr (Col.) Arun Harith (Sr. Consultant & Head of Department-Biochemistry, Medanta Medicity, New Delhi) highlighted the growing need of database for improving test outcomes. On the other hand, Dr (Col.) Jyoti Kotwal (Chairperson & Prof.- Dept. of Hematology, Sir Gangaram Hospital, New Delhi) spoke on ‘Clinical Utility of Advanced Hematology Parameters.’ She emphasized on how the latest automation in hematology helps in the enumeration of the different parameters such as IPF, Ret He, Immature Granulocytes, NRBC, etc. and how these parameters help in early diagnosis of diseases.
The sessions were chaired by Dr Meera Sikka, Head of Department of Pathology, University College of Medical Sciences. (Image on the Left)
Transasia offers the entire range of semi and fully automated analyzers and reagents in biochemistry and hematology. The latest in clinical chemistry is a fully automated, random access clinical chemistry analyzer, XL 1000 with a throughput of 1040 tests/ hr. It offers a host of key features such as sample clot detection, permanent hard glass cuvettes and four channel direct ISE measurement, among others, making it an ideal choice for high volume labs.
The seminar received an overwhelming response with full-house participation. The over 70 attendees comprised pathologists, physicians and clinicians from reputed Government institutions such as Delhi Cancer Institute, IHBAS, Swami Dayanand Hospital, Rajiv Gandhi Super Specialty Hospital, Hegdewar Hospital, LBS Hospital and private institutes such as MAX Healthcare, Kailash Healthcare Ltd., Yashoda Super Specialty Hospital, Dr. Lal PathLabs, Metropolis, SRL Diagnostics, etc.
Speaking on the occasion a spokesperson for Transasia Bio-Medicals said, “There is an alarming burden on the society from both communicable and non communicable diseases in India. 70 percent of the treatment decisions are based on lab results. Yet, less than 30 percent of the Indian population has ever got their blood test done. The major chunk of the 70 percent population is in the smaller towns. At Transasia, we are committed to reaching out to the pathologists and clinicians in every nook and corner of the country, so that they are well equipped to cater to this population.TSS Ace is a unique platform that empowers the pathologists with the technological advances and encourages exchange of scientific updates, backed by expertise and experience. ”
Over the years, TSS Ace has grown in popularity and has become Transasia’s identity. It has been well accepted as a successful forum and benefits more than 800 pathologists and clinicians annually.
*Note: This news is based on a press release.